Researchers in Germany have just discovered an antibiotic that is produced by bacteria found in our noses and is able to kill MRSA. This comes from an article posted on Stat News. DirectorsTalk caught up with the CEO of Opibiotix Health Plc (LON:OPTI) for his thoughts.
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This is good news in the fight against MRSA and consistent with our research an product development. OptiBiotix announced the filing of patents in May 2016 which protects advances made in its skin division in identifying microbial proteins which have the potential to prevent Health Care Acquired Infections (“HCAI”) caused by antimicrobial resistant (“AMR”) superbugs such as MRSA. These proteins prevent skin damage, stop pathogenic bacteria from growing, and most importantly prevent them from reattaching, reducing the risk of reinfection from MRSA. The mechanism of action is different from current treatments which may kill bacteria but then allow reattachment with more resistant bacteria and is an exciting advance on current therapies.”
